Sangamo Biosciences (SGMO) 13.99 $SGMO
Sangamo Biosciences Has Returned 26.3% Since SmarTrend Recommendation (SGMO)
Comtex SmarTrend(R) - Wed Apr 16, 9:36AM CDT
SmarTrend identified a Downtrend for Sangamo Biosciences (NASDAQ:SGMO) on March 25th, 2014 at $19.07. In approximately 3 weeks, Sangamo Biosciences has returned 26.30% as of today's recent price of $14.05.
Valuation Doesn't Equal Share Price (and That Goes Double for Biotech)
Brian Orelli, The Motley Fool - Motley Fool - Mon Apr 14, 6:52PM CDT
Most investors realize that share price is meaningless when comparing companies. A company at $50 per share might actually be worth more than a company at $100 per share because a company's value is determined by the number of outstanding shares in...
'Mad Money' Lightning Round: I Don't See a BioMarin Rally
at The Street - Fri Apr 11, 5:00AM CDT
Cramer likes Service Corp. over Carriage Services and Magnum Hunter Resources over Swift Energy.
Jim Cramer's 'Mad Money' Recap: Blame China, Greece for the Meltdown
at The Street - Thu Apr 10, 7:24PM CDT
While everything went right in America, everything was going wrong in the rest of the world -- and that apparently makes all the difference, Cramer says.
Sangamo Biosciences Has Returned 17.0% Since SmarTrend Recommendation (SGMO)
Comtex SmarTrend(R) - Wed Apr 09, 9:10AM CDT
SmarTrend identified a Downtrend for Sangamo Biosciences (NASDAQ:SGMO) on March 25th, 2014 at $19.07. In approximately 2 weeks, Sangamo Biosciences has returned 17.03% as of today's recent price of $15.82.
Top Gainers Updates -- Research on Sangamo BioSciences, Synthesis Energy Systems, OXiGENE, and Affymetrix
PR Newswire - Tue Apr 01, 8:08AM CDT
On Monday, March 31, 2014, the US markets saw a positive sentiment, as the NASDAQ Composite closed at 4,198.99, up 1.04%, the Dow Jones Industrial Average ended the session at 16,457.66, up 0.82% and the S&P 500 edged 0.79% higher to finish the trading session at 1,872.34. The gains were broad based as nine out of 10 sectors ended the session in positive. A number of stocks saw large movements, including Sangamo BioSciences Inc. (NASDAQ: SGMO), Synthesis Energy Systems Inc. (NASDAQ: SYMX), OXiGENE Inc. (NASDAQ: OXGN) and Affymetrix Inc. (NASDAQ: AFFX). Free technical research on SGMO, SYMX, OXGN and AFFX can be downloaded upon signing up at:
Sangamo Biosciences Has Returned 91.4% Since SmarTrend Recommendation (SGMO)
Comtex SmarTrend(R) - Tue Mar 25, 9:09AM CDT
SmarTrend identified an Uptrend for Sangamo Biosciences (NASDAQ:SGMO) on November 18th, 2013 at $10.38. In approximately 4 months, Sangamo Biosciences has returned 91.42% as of today's recent price of $19.86.
Biotech Stock Mailbag: Amarin, Cytrx, Sangamo and 'Story Stocks'
at The Street - Fri Mar 21, 6:00AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
Sangamo BioSciences prices public offering of 4.44m common shares
M2 - Fri Mar 21, 4:51AM CDT
DNA-binding protein company Sangamo BioSciences (NasdaqGS:SGMO) said on Thursday that it has priced a public offering of 4,444,444 common shares.
Sangamo BioSciences Announces Pricing Of Public Offering Of Common Stock
PR Newswire - Thu Mar 20, 6:52PM CDT
Sangamo BioSciences, Inc. (Nasdaq: SGMO) today announced the pricing of an underwritten public offering of common stock consisting of 4,444,444 shares at a public offering price of $22.50 per share. The gross proceeds to Sangamo from the public offering are expected to be approximately $100 million, before deducting underwriting discounts and commissions and other estimated offering expenses. In connection with this offering, Sangamo granted to the underwriters a 30-day option to purchase an additional 666,666 shares of common stock. The offering is expected to close on or about March 26, 2014, subject to customary closing conditions.
Sangamo BioSciences expects USD100m from public offering of common shares
M2 - Thu Mar 20, 6:24AM CDT
DNA-binding protein company Sangamo BioSciences (NasdaqGS:SGMO) disclosed on Wednesday the start of a USD100m public offering of its common stock.
Sangamo BioSciences Announces Public Offering Of Common Stock
PR Newswire - Wed Mar 19, 3:01PM CDT
Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that it has commenced a $100 million underwritten public offering of shares of its common stock. All of the shares in the offering are to be sold by Sangamo. Sangamo intends to grant the underwriters a 30 day option to purchase up to 15% of the number of shares of common stock sold in the offering. Sangamo intends to use the proceeds from this offering for working capital and other general corporate purposes, including support for continuing research and development of ZFP Therapeutic product candidates and research programs (including research stage programs for monogenic diseases and cancer immunotherapy), manufacturing capabilities for clinical and commercial production, clinical trials and business development activities and, if opportunities arise, acquisitions of businesses, products, technologies or licenses that are complementary to our business.
Watch These 3 High-Risk Stocks
at The Street - Tue Mar 11, 8:27AM CDT
Chris Lau, Kapitall: These high-risk stocks have made big moves. Is it time for you to make a move? High-risk [...]
Marketing Authorization Applications, Quarterly Dividends, Publication of Clinical Trial Data, Acquisitions, and Financial Results - Analyst Notes on Regeneron, Amgen, Sangamo, Alnylam, and Agios
PR Newswire - Tue Mar 11, 8:08AM CDT
Today, Analysts Review released its analysts' notes regarding Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), Amgen, Inc. (NASDAQ: AMGN), Sangamo BioSciences, Inc. (NASDAQ: SGMO), Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY), and Agios Pharmaceuticals, Inc. (NASDAQ: AGIO). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
What You Need to Know About Sangamo Biosciences' Surge
Todd Campbell, The Motley Fool - Motley Fool - Mon Mar 10, 5:00PM CDT
Sangamo Biosciences' promising early stage HIV drug SB-728-T may someday change how doctors treat patients. Results from a small, 14 person phase 1 trial suggest that while the drug doesn't eradicate HIV from patients, it may someday offer patients...
This Week in Biotech: Put It in Print
Sean Williams, The Motley Fool - Motley Fool - Sat Mar 08, 1:05PM CST
With the SPDR S&P Biotech Index up 62% over the trailing-12-month period , it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and...
Sangamo Soars on Positive Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 07, 10:50AM CST
Sangamo's HIV candidate SB-728-T has shown great promise.
Jim Cramer: Happy Birthday, You Bogus Bull Market
at The Street - Fri Mar 07, 10:22AM CST
You've rallied 177%, yet many don't seem to believe you exist.
Sangamo Biosciences (SGMO) Worth Watching: Stock Surges 17.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Mar 07, 8:25AM CST
Sangamo Biosciences was a big mover last session, as the company saw its shares rise just over 17% on the day.
Top Gainers Pre-Market Notes: Pixelworks, Yingli Green Energy Holding, McDermott Intl., and Sangamo Biosciences
PR Newswire - Fri Mar 07, 7:00AM CST
The US markets saw a mixed sentiment on Thursday, March 06, 2014, with the NASDAQ Composite closing at 4,352.13, down 0.13%, the Dow Jones Industrial Average ending the session at 16,421.89, up 0.38% and the S&P 500 edging 0.17% higher to finish the trading session at 1,877.03. During the session gains in the Financials, Energy and Industrials sectors positively impacted the broader market, while some retraction came in from Health Care, Consumer Staples and Utilities sectors. A number of stocks saw large movements, including Pixelworks Inc. (NASDAQ: PXLW), Yingli Green Energy Holding Company Ltd (NYSE: YGE), McDermott International Inc. (NYSE: MDR), and Sangamo BioSciences Inc. (NASDAQ: SGMO), which were amongst the top gainers for the session. Free research on these five companies can be accessed at:
Sangamo Biosciences Has Returned 26.3% Since SmarTrend Recommendation (SGMO)
Comtex SmarTrend(R) - Wed Apr 16, 9:36AM CDT
SmarTrend identified a Downtrend for Sangamo Biosciences (NASDAQ:SGMO) on March 25th, 2014 at $19.07. In approximately 3 weeks, Sangamo Biosciences has returned 26.30% as of today's recent price of $14.05.
Valuation Doesn't Equal Share Price (and That Goes Double for Biotech)
Brian Orelli, The Motley Fool - Motley Fool - Mon Apr 14, 6:52PM CDT
Most investors realize that share price is meaningless when comparing companies. A company at $50 per share might actually be worth more than a company at $100 per share because a company's value is determined by the number of outstanding shares in...
'Mad Money' Lightning Round: I Don't See a BioMarin Rally
at The Street - Fri Apr 11, 5:00AM CDT
Cramer likes Service Corp. over Carriage Services and Magnum Hunter Resources over Swift Energy.
Jim Cramer's 'Mad Money' Recap: Blame China, Greece for the Meltdown
at The Street - Thu Apr 10, 7:24PM CDT
While everything went right in America, everything was going wrong in the rest of the world -- and that apparently makes all the difference, Cramer says.
Sangamo Biosciences Has Returned 17.0% Since SmarTrend Recommendation (SGMO)
Comtex SmarTrend(R) - Wed Apr 09, 9:10AM CDT
SmarTrend identified a Downtrend for Sangamo Biosciences (NASDAQ:SGMO) on March 25th, 2014 at $19.07. In approximately 2 weeks, Sangamo Biosciences has returned 17.03% as of today's recent price of $15.82.
Top Gainers Updates -- Research on Sangamo BioSciences, Synthesis Energy Systems, OXiGENE, and Affymetrix
PR Newswire - Tue Apr 01, 8:08AM CDT
On Monday, March 31, 2014, the US markets saw a positive sentiment, as the NASDAQ Composite closed at 4,198.99, up 1.04%, the Dow Jones Industrial Average ended the session at 16,457.66, up 0.82% and the S&P 500 edged 0.79% higher to finish the trading session at 1,872.34. The gains were broad based as nine out of 10 sectors ended the session in positive. A number of stocks saw large movements, including Sangamo BioSciences Inc. (NASDAQ: SGMO), Synthesis Energy Systems Inc. (NASDAQ: SYMX), OXiGENE Inc. (NASDAQ: OXGN) and Affymetrix Inc. (NASDAQ: AFFX). Free technical research on SGMO, SYMX, OXGN and AFFX can be downloaded upon signing up at:
Sangamo Biosciences Has Returned 91.4% Since SmarTrend Recommendation (SGMO)
Comtex SmarTrend(R) - Tue Mar 25, 9:09AM CDT
SmarTrend identified an Uptrend for Sangamo Biosciences (NASDAQ:SGMO) on November 18th, 2013 at $10.38. In approximately 4 months, Sangamo Biosciences has returned 91.42% as of today's recent price of $19.86.
Biotech Stock Mailbag: Amarin, Cytrx, Sangamo and 'Story Stocks'
at The Street - Fri Mar 21, 6:00AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
Sangamo BioSciences prices public offering of 4.44m common shares
M2 - Fri Mar 21, 4:51AM CDT
DNA-binding protein company Sangamo BioSciences (NasdaqGS:SGMO) said on Thursday that it has priced a public offering of 4,444,444 common shares.
Sangamo BioSciences Announces Pricing Of Public Offering Of Common Stock
PR Newswire - Thu Mar 20, 6:52PM CDT
Sangamo BioSciences, Inc. (Nasdaq: SGMO) today announced the pricing of an underwritten public offering of common stock consisting of 4,444,444 shares at a public offering price of $22.50 per share. The gross proceeds to Sangamo from the public offering are expected to be approximately $100 million, before deducting underwriting discounts and commissions and other estimated offering expenses. In connection with this offering, Sangamo granted to the underwriters a 30-day option to purchase an additional 666,666 shares of common stock. The offering is expected to close on or about March 26, 2014, subject to customary closing conditions.
Sangamo BioSciences expects USD100m from public offering of common shares
M2 - Thu Mar 20, 6:24AM CDT
DNA-binding protein company Sangamo BioSciences (NasdaqGS:SGMO) disclosed on Wednesday the start of a USD100m public offering of its common stock.
Sangamo BioSciences Announces Public Offering Of Common Stock
PR Newswire - Wed Mar 19, 3:01PM CDT
Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that it has commenced a $100 million underwritten public offering of shares of its common stock. All of the shares in the offering are to be sold by Sangamo. Sangamo intends to grant the underwriters a 30 day option to purchase up to 15% of the number of shares of common stock sold in the offering. Sangamo intends to use the proceeds from this offering for working capital and other general corporate purposes, including support for continuing research and development of ZFP Therapeutic product candidates and research programs (including research stage programs for monogenic diseases and cancer immunotherapy), manufacturing capabilities for clinical and commercial production, clinical trials and business development activities and, if opportunities arise, acquisitions of businesses, products, technologies or licenses that are complementary to our business.
Watch These 3 High-Risk Stocks
at The Street - Tue Mar 11, 8:27AM CDT
Chris Lau, Kapitall: These high-risk stocks have made big moves. Is it time for you to make a move? High-risk [...]
Marketing Authorization Applications, Quarterly Dividends, Publication of Clinical Trial Data, Acquisitions, and Financial Results - Analyst Notes on Regeneron, Amgen, Sangamo, Alnylam, and Agios
PR Newswire - Tue Mar 11, 8:08AM CDT
Today, Analysts Review released its analysts' notes regarding Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), Amgen, Inc. (NASDAQ: AMGN), Sangamo BioSciences, Inc. (NASDAQ: SGMO), Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY), and Agios Pharmaceuticals, Inc. (NASDAQ: AGIO). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
What You Need to Know About Sangamo Biosciences' Surge
Todd Campbell, The Motley Fool - Motley Fool - Mon Mar 10, 5:00PM CDT
Sangamo Biosciences' promising early stage HIV drug SB-728-T may someday change how doctors treat patients. Results from a small, 14 person phase 1 trial suggest that while the drug doesn't eradicate HIV from patients, it may someday offer patients...
This Week in Biotech: Put It in Print
Sean Williams, The Motley Fool - Motley Fool - Sat Mar 08, 1:05PM CST
With the SPDR S&P Biotech Index up 62% over the trailing-12-month period , it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and...
Sangamo Soars on Positive Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 07, 10:50AM CST
Sangamo's HIV candidate SB-728-T has shown great promise.
Jim Cramer: Happy Birthday, You Bogus Bull Market
at The Street - Fri Mar 07, 10:22AM CST
You've rallied 177%, yet many don't seem to believe you exist.
Sangamo Biosciences (SGMO) Worth Watching: Stock Surges 17.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Mar 07, 8:25AM CST
Sangamo Biosciences was a big mover last session, as the company saw its shares rise just over 17% on the day.
Top Gainers Pre-Market Notes: Pixelworks, Yingli Green Energy Holding, McDermott Intl., and Sangamo Biosciences
PR Newswire - Fri Mar 07, 7:00AM CST
The US markets saw a mixed sentiment on Thursday, March 06, 2014, with the NASDAQ Composite closing at 4,352.13, down 0.13%, the Dow Jones Industrial Average ending the session at 16,421.89, up 0.38% and the S&P 500 edging 0.17% higher to finish the trading session at 1,877.03. During the session gains in the Financials, Energy and Industrials sectors positively impacted the broader market, while some retraction came in from Health Care, Consumer Staples and Utilities sectors. A number of stocks saw large movements, including Pixelworks Inc. (NASDAQ: PXLW), Yingli Green Energy Holding Company Ltd (NYSE: YGE), McDermott International Inc. (NYSE: MDR), and Sangamo BioSciences Inc. (NASDAQ: SGMO), which were amongst the top gainers for the session. Free research on these five companies can be accessed at:
